Takeda s GAMMAGARD LIQUID® Approved by U S FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) financialpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialpost.com Daily Mail and Mail on Sunday newspapers.
The FDA has approved Hyqvia (immune globulin infusion 10% [human] with recombinant human hyaluronidase) for chronic inflammatory demyelinating polyneuropathy.
TakedaTSE4502NYSETAK today announced full results from the pivotal Phase 3 ADVANCECIDP 1 clinical trial investigating HYQVIA Immune Globulin Infusion 10 Human with Recombinant Human Hyaluronidase as maintenance therapy in adult patients with chronic inflammatory demyelinating polyneuropathy CIDP.
Pivotal Phase 3 Findings with HYQVIA [Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase] Showed a Clinically Significant Reduction in Relapse Rate as well as a Delayed Time to. | June 20, 2023